BR112016002171A2 - método, composição estéril e injetável e método para preparar uma composição estéril e injetável - Google Patents

método, composição estéril e injetável e método para preparar uma composição estéril e injetável

Info

Publication number
BR112016002171A2
BR112016002171A2 BR112016002171A BR112016002171A BR112016002171A2 BR 112016002171 A2 BR112016002171 A2 BR 112016002171A2 BR 112016002171 A BR112016002171 A BR 112016002171A BR 112016002171 A BR112016002171 A BR 112016002171A BR 112016002171 A2 BR112016002171 A2 BR 112016002171A2
Authority
BR
Brazil
Prior art keywords
sterile
injectable composition
preparing
mepivacaine
salt
Prior art date
Application number
BR112016002171A
Other languages
English (en)
Portuguese (pt)
Inventor
Bourdon François
Meunier Stéphane
Original Assignee
Teoxane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51570796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016002171(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teoxane filed Critical Teoxane
Publication of BR112016002171A2 publication Critical patent/BR112016002171A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24Phosphorous; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/12Phosphorus-containing materials, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/20Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/524Preservatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91Injection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402Anaestetics, analgesics, e.g. lidocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/06Flowable or injectable implant compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112016002171A 2013-07-30 2014-07-29 método, composição estéril e injetável e método para preparar uma composição estéril e injetável BR112016002171A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/954,360 US9421198B2 (en) 2013-07-30 2013-07-30 Composition comprising hyaluronic acid and mepivacaine
PCT/IB2014/063503 WO2015015407A1 (en) 2013-07-30 2014-07-29 Composition comprising hyaluronic acid and mepivacaine

Publications (1)

Publication Number Publication Date
BR112016002171A2 true BR112016002171A2 (pt) 2017-08-01

Family

ID=51570796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002171A BR112016002171A2 (pt) 2013-07-30 2014-07-29 método, composição estéril e injetável e método para preparar uma composição estéril e injetável

Country Status (21)

Country Link
US (9) US9421198B2 (enExample)
EP (2) EP3027186B1 (enExample)
JP (1) JP6543625B2 (enExample)
KR (2) KR20210110406A (enExample)
CN (2) CN105682657A (enExample)
AU (1) AU2014298046B2 (enExample)
BR (1) BR112016002171A2 (enExample)
CA (1) CA2919792C (enExample)
CY (1) CY1122648T1 (enExample)
DK (2) DK3574901T3 (enExample)
ES (2) ES2743755T3 (enExample)
HR (1) HRP20191345T1 (enExample)
HU (1) HUE045969T2 (enExample)
LT (1) LT3027186T (enExample)
PL (2) PL3574901T3 (enExample)
PT (2) PT3574901T (enExample)
RS (1) RS59108B1 (enExample)
RU (1) RU2670617C2 (enExample)
SI (1) SI3027186T1 (enExample)
SM (1) SMT201900494T1 (enExample)
WO (1) WO2015015407A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421198B2 (en) 2013-07-30 2016-08-23 Teoxane Composition comprising hyaluronic acid and mepivacaine
FR3015290B1 (fr) * 2013-12-23 2017-01-13 Lab Vivacy Compositions d'acide hyaluronique compreant de la mepivacaine
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
FR3036035B1 (fr) 2015-05-11 2018-10-05 Laboratoires Vivacy Compositions comprenant au moins un polyol et au moins un anesthesique
EP3165233B1 (en) * 2015-08-28 2021-08-18 Latvijas Universitate Biomaterial for treatment of acute and chronic skin wounds
FR3058064B1 (fr) 2016-10-28 2020-08-07 Lab Vivacy Composition a base d'acide hyaluronique comprenant de la mepivacaine
EP3354258A1 (en) * 2017-01-31 2018-08-01 Teoxane SA Use of a cohesive gel as a matrix material in a periodontal pocket
WO2018159983A1 (ko) * 2017-02-28 2018-09-07 (주)시지바이오 피부 주입용 조성물
CN111787915A (zh) * 2017-04-12 2020-10-16 尤里根制药股份有限公司 注射器中包含局部麻醉剂、缓冲剂和糖胺聚糖的稳定性提高的制品
KR102091452B1 (ko) * 2017-12-19 2020-03-20 대화제약 주식회사 국소 마취제 및 히알루론산 하이드로겔을 포함하는 사전충전형 주사기의 제조방법
ES2965417T3 (es) * 2017-12-29 2024-04-15 Matex Lab S P A Método para preparar relleno con una base de ácido hialurónico, que comprende una etapa de neutralización
CA3089896A1 (en) * 2018-02-06 2019-08-15 Regen Lab Sa Cross-linked hyaluronic acids and combinations with prp/bmc
CN110721142A (zh) * 2018-07-17 2020-01-24 上海美白臻生物科技有限公司 一种全效型微整专用玻尿酸制备工艺
CA3122116C (en) * 2018-12-20 2023-07-18 Lg Chem, Ltd. Filler having excellent filler properties comprising hyaluronic acid hydrogel
EP3969057B1 (en) 2019-05-17 2025-12-17 The Governing Council of the University of Toronto Sustained release local anesthetic hydrogel composition
US12414917B2 (en) 2019-09-13 2025-09-16 University Of Utah Research Foundation Opioid independent surgical anesthetic
FR3105729B1 (fr) * 2019-12-31 2023-07-21 Mrs Biotech Composition pour la gestion du poids d’un sujet
EP3861996A1 (en) 2020-02-04 2021-08-11 I+Med S. Coop. Controlled release system of phytocannabinoids formulations soluble in aqueous media, methods and uses thereof
TWI731660B (zh) * 2020-04-24 2021-06-21 透策生技股份有限公司 利用加壓手段以加速注射式填充物分散的處理方法
US20230321319A1 (en) * 2020-08-18 2023-10-12 Innate S.R.L. Injectable composition and use of said composition
CN113896915B (zh) * 2021-11-10 2024-02-13 爱美客技术发展股份有限公司 一种凝胶材料及其制备方法与应用
JP7733824B2 (ja) * 2021-11-10 2025-09-03 ▲愛▼美客技▲術▼▲発▼展股▲ふん▼有限公司 ゲル材料、その調製方法及び使用
WO2023158281A1 (ko) * 2022-02-21 2023-08-24 이광미 금속 티오옥토일 히알루로네이트 복합체 및 그의 용도
KR102451308B1 (ko) * 2022-02-21 2022-10-07 이광미 금속 티오옥토일 히알루로네이트 복합체 및 이의 제조 방법
KR102559788B1 (ko) * 2022-04-21 2023-07-27 주식회사 티앤알바이오팹 다단계 탈세포화된 조직 매트릭스 및 이의 제조방법
CN117357699B (zh) * 2022-07-06 2024-12-10 渼颜空间(河北)生物科技有限公司 一种具有祛斑功效的透明质酸钠组合物及其制备方法和其应用
CN115737506B (zh) * 2022-12-16 2023-09-05 江苏亨瑞生物医药科技有限公司 一种含有胶原蛋白的面膜及其制备方法
KR102680817B1 (ko) * 2023-06-02 2024-07-03 주식회사 에스씨엘 히알루론산 필러의 제조방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799679A (en) 1955-04-28 1957-07-16 Bofors Ab Process of preparing amides of heterocyclic carboxylic acids
GB826668A (en) 1955-06-27 1960-01-20 Crookes Lab Ltd Process for manufacturing basic carboxamides
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
DE10246340A1 (de) 2002-10-04 2004-04-29 Wohlrab, David, Dr. Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung
US8124120B2 (en) * 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
US20050142152A1 (en) 2003-12-30 2005-06-30 Leshchiner Adelya K. Polymeric materials, their preparation and use
JP2007518821A (ja) 2004-01-23 2007-07-12 オハイオ ユニバーシティー Pggの分離および精製
KR101239037B1 (ko) * 2004-11-15 2013-03-04 가부시키가이샤 시세이도 가교 히알루론산 겔의 제조 방법
CN101336142B (zh) 2005-12-06 2012-12-05 安格斯公司 用于多孔垫的模塑可旋转基体
BRPI0913189A2 (pt) 2008-05-30 2016-01-12 Allergan Inc dispositivo de injeção para cargas de aumento de tecido mole, agentes bioativos e outros materiais biocompatíveis em forma líquida ou gel
US8450475B2 (en) * 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
FR2945293B1 (fr) 2009-05-11 2011-06-17 Teoxane Procede de preparation d'un gel reticule.
US9050246B2 (en) 2009-05-29 2015-06-09 Galderma Research & Development Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
US20110171286A1 (en) 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US20110171310A1 (en) 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
FR2962040B3 (fr) * 2010-07-05 2012-08-10 Alain Villette Composition injectable comprenant un medicament injectable et un gel
BR112013011282B1 (pt) 2010-11-08 2019-05-14 Allergan Industrie Sas Composição de material de enchimento de tecido mole e método de preparação da mesma
EP2484387A1 (en) 2011-02-03 2012-08-08 Q-Med AB Hyaluronic acid composition
EP2606828B1 (en) 2011-12-20 2018-04-11 Angioclinic AG Hyaluronic acid and its use for treating venous insufficiency and varicose veins
US9241921B2 (en) * 2011-05-02 2016-01-26 Pankaj Modi Photosensitizer composition for treating skin disorders
RU2624239C2 (ru) * 2011-06-03 2017-07-03 Аллерган, Инк. Составы кожного наполнителя, включая антиоксиданты
FR2979539B1 (fr) 2011-09-05 2013-09-27 Teoxane Composition sterile dermo-injectable
US20130131632A1 (en) 2011-11-18 2013-05-23 Allergan, Inc. Injection device and method for diluting an injectable fluid
FR2991876B1 (fr) * 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
CN102805882B (zh) * 2012-08-28 2014-04-23 华熙福瑞达生物医药有限公司 一种软组织填充剂在使用前与麻醉剂注射液混合的方法
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
WO2014093645A2 (en) * 2012-12-13 2014-06-19 Precision Dermatology, Inc. Topical formulations for increasing the dermal concentration of hyaluronic acid
WO2014165113A1 (en) 2013-03-12 2014-10-09 Allergan Holdings France S.A.S. Cross-linked hyaluronic acid threads for treatment of striae
US9421198B2 (en) 2013-07-30 2016-08-23 Teoxane Composition comprising hyaluronic acid and mepivacaine
FR3015290B1 (fr) 2013-12-23 2017-01-13 Lab Vivacy Compositions d'acide hyaluronique compreant de la mepivacaine

Also Published As

Publication number Publication date
SI3027186T1 (sl) 2019-09-30
CA2919792A1 (en) 2015-02-05
CA2919792C (en) 2020-01-28
US10322212B2 (en) 2019-06-18
AU2014298046A1 (en) 2016-03-10
HRP20191345T1 (hr) 2019-11-01
DK3574901T3 (da) 2022-03-07
US9789226B2 (en) 2017-10-17
US9421198B2 (en) 2016-08-23
US20200390940A1 (en) 2020-12-17
US20220362439A1 (en) 2022-11-17
HUE045969T2 (hu) 2020-01-28
CN113648459A (zh) 2021-11-16
US10786601B2 (en) 2020-09-29
CY1122648T1 (el) 2021-05-05
US11406738B2 (en) 2022-08-09
RU2016106152A (ru) 2017-08-31
US20180021480A1 (en) 2018-01-25
US20190184065A1 (en) 2019-06-20
US20160325021A1 (en) 2016-11-10
DK3027186T3 (da) 2019-09-16
AU2014298046B2 (en) 2018-11-08
EP3027186B1 (en) 2019-06-19
US9498562B1 (en) 2016-11-22
PL3574901T3 (pl) 2022-05-09
CN105682657A (zh) 2016-06-15
LT3027186T (lt) 2019-09-10
EP3027186A1 (en) 2016-06-08
US9925309B2 (en) 2018-03-27
US20180169304A1 (en) 2018-06-21
JP6543625B2 (ja) 2019-07-10
EP3574901A1 (en) 2019-12-04
ES2743755T3 (es) 2020-02-20
EP3574901B1 (en) 2022-01-26
PT3574901T (pt) 2022-04-08
KR20160038047A (ko) 2016-04-06
WO2015015407A1 (en) 2015-02-05
RU2670617C2 (ru) 2018-10-24
PL3027186T3 (pl) 2019-12-31
PT3027186T (pt) 2019-09-09
US20160166554A1 (en) 2016-06-16
JP2016527264A (ja) 2016-09-08
US20150038457A1 (en) 2015-02-05
US10413637B2 (en) 2019-09-17
SMT201900494T1 (it) 2019-11-13
RS59108B1 (sr) 2019-09-30
US20180318469A1 (en) 2018-11-08
ES2910519T3 (es) 2022-05-12
KR20210110406A (ko) 2021-09-07

Similar Documents

Publication Publication Date Title
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
BR112016006182A8 (pt) composição veterinária de longa duração, uso de uma isoxazolina espirocíclica para preparação da mesma, bem como processo para a preparação de uma microesfera
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015005940A2 (pt) processo para a preparação de nanopartículas terapêuticas
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
BR112015024659A8 (pt) formulação farmacêutica aquosa, seu uso, método de tratamento de diabetes mellitus e artigo de fabricação
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
BR112015015699A2 (pt) composição aquosa injetável, método de preparação de uma composição aquosa injetável método para o tratamento ou prevenção de condições de dor e/ou inflamação e uso da composição
BR112016011472A2 (pt) tienopirimidinas como inibidores de mknk1 e mknk2
BR112016007487A2 (pt) composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica
BR112016000338A8 (pt) composto enriquecido em deutério de fórmula estrutural i, composição farmacêutica, e usos de um composto
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112012018154A2 (pt) agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112013001462B8 (pt) Composições
BR112018001387A2 (pt) composição de absorção percutânea, e, agente para promover a absorbabilidade transdérmica de um medicamento básico
BR112018012765A2 (pt) composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico.
BR112014031306A2 (pt) composição farmacêutica e respectivos usos
BR112015022084A2 (pt) composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]